MAI Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-23,968
Closed -$517K 5022
2025
Q4
$517K Sell
23,968
-154
-0.6% -$2.99K ﹤0.01% 949
2025
Q3
$368K Sell
24,122
-55
-0.2% -$716 ﹤0.01% 1028
2025
Q2
$214K Sell
24,177
-1,846
-7% -$16.2K ﹤0.01% 1145
2025
Q1
$204K Sell
26,023
-74,567
-74% -$624K ﹤0.01% 1111
2024
Q4
$1.06M Sell
100,590
-6,943
-6% -$84.3K 0.01% 618
2024
Q3
$1.41M Buy
107,533
+1,031
+1% +$15.7K 0.01% 467
2024
Q2
$1.5M Sell
106,502
-5,103
-5% -$83.2K 0.01% 481
2024
Q1
$1.89M Buy
111,605
+4,525
+4% +$67.4K 0.02% 415
2023
Q4
$1.51M Buy
107,080
+61,857
+137% +$727K 0.02% 378
2023
Q3
$466K Sell
45,223
-6,047
-12% -$81K 0.01% 661
2023
Q2
$845K Buy
+51,270
New +$667K 0.01% 467

Other funds holding AVDL

MAI Capital Management's AVDL Position: Q1 2026 in Review

MAI Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 23,968 shares — an estimated $517K sold.

MAI Capital Management first reported a position in AVDL in Q2 2023 and held it in 11 quarters. The position peaked at $1.89M in Q1 2024. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • MAI Capital Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • MAI Capital Management sold 23,968 Avadel Pharmaceuticals shares in Q1 2026, an estimated $517K.
  • MAI Capital Management first reported a position in Avadel Pharmaceuticals in Q2 2023 and held it in 11 quarters.
  • MAI Capital Management's Avadel Pharmaceuticals position peaked at $1.89M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.